Kadmon Corporation

Last updated
Kadmon Corporation, LLC.
Company type Subsidiary
Industry Biotechnology
Founded2009;15 years ago (2009)
Founder Samuel D. Waksal
Headquarters
450 East 29th Street,
New York, NY 10016
,
United States
Number of locations
4
Key people
Harlan W. Waksal, MD (CEO)
Anastasios G. Konidaris (Interim chairman)
Productscapecitabine, dofetilide, entecavir, ribavirin, temozolomide, tetrabenazine, tobramycin
Number of employees
101 [1]
Parent Sanofi
Website kadmon.com

Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal, [2] [3] founder and former CEO of ImClone Systems, a company now fully merged into Eli Lilly. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001 ImClone stock trading case. When released in 2009 he was barred from serving as an officer for any publicly traded company but Kadmon was privately financed. [4] [5]

Contents

In September 2014, amid plans to take the company to an IPO Harlan W. Waksal, brother of Samuel Waksal, became President and Chief Executive Officer while Samuel Waksal remained on with the title Chief of Innovation, Science and Strategy. [6] In early 2016 Sam Waksal left Kadmon and in June the company filed paperwork for its IPO. [7] [8] On July 27, 2016 the company's stock began trading on the NYSE under the symbol KDMN [9] but switched to NASDAQ in October 2020. [10] On 8 September 2021, Sanofi announced it would acquire the company for $1.9 billion. [11] The deal completed in November and its stock was deregistered as it became a subsidiary of Sanofi.

As of 2019 Kadmon had ongoing clinical trials for Belumosudil in specific fibrotic and neurodegenerative diseases and tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. [12]

Product acquisitions

During Waksal's leadership of ImClone the company was engaged in early stage research projects for 15 years before filing its first drug application. [13] Kadmon however immediately began acquiring drugs further advanced - either already marketed in the US or in the later stages of clinical development. [14] It acquired the Warrendale, PA-based company Three Rivers Pharmaceuticals and their Ribasphere and topotecan products. [15] It also signed an agreement with Ontario, Canada-based Valeant Pharmaceuticals for their Hepatitis C drugs ribavirin and taribavirin (now KD024). [16] Cancer drugs XL647 [13] and XL844 [14] were acquired from Exelixis. An inhibitor of several protein kinases, tesevatinib (XL647, KD019) entered Phase II clinical trial for certain indications of non-small cell lung cancer. [17] [18] and in polycystic kidney disease. [19] XL844 is an inhibitor of protein kinases Chk1 and Chk2 and may increase the sensitivity of cancer cells to radiation therapy. [20]

In an acquisition atypical for a biotechnology company, an 1800-year-old Chinese herbal formula was added to Kadmon's portfolio. PhytoCeutica's PHY906 (KD018) is a formula of four botanical products that had long been used for the treatment of gastrointestinal distress. Preclinical studies have shown it to enhance the therapeutic activity of several anticancer agents. [21] In 2014 KD018 was in a Phase II trial in combination with irinotecan in metastatic colon cancer. [22]

In 2011 the company acquired rights from Brighton, MA-based Nano Terra Inc. [23] for their Pharmacomer Technology research platform and three drug candidates in clinical development. [24] These compounds include SLx-2119 (KD025), an inhibitor to Rho kinase 2 (ROCK2) with possible potential in fibrotic disease [25] and focal cerebral ischemia. [26] SLx-4090 (KD026) is a triglyceride transfer protein (MTP) inhibitor being explored for metabolic disorders. [27] SLx-2101 (KD027) is a phosphodiesterase 5 (PDE5) inhibitor, a class of drug used in the treatment of erectile dysfunction. [28]

In 2012 the rights to salirasib (KD032), a Ras antagonist in development for cancer therapy, [29] were acquired from Concordia Pharmaceuticals of Fort Lauderdale, FL. [30] It also acquired the rights from Burlington, MA-based Dyax Corp. for DX-2400, [31] a Matrix metalloproteinase-14 (MPP-14) targeted monoclonal antibody intended to inhibit tumor blood vessel formation and metastasis. [32]

Products

As of 2019 Kadmon produces several generic drugs approved by the Food and Drug Administration in the United States.

Related Research Articles

<span class="mw-page-title-main">Valproate</span> Medication used for epilepsy, bipolar disorder and migraine

Valproate are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.

ImClone Systems LLC was a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey, and its research headquarters in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully-owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company.

Samuel D. Waksal is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration (FDA) Waksal became involved in an insider trading scandal revolving around improper communications with personal friends and family members. He was convicted of several securities violations, served time in federal prison, and was released.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Erlotinib</span> Medication for treatment of non-small-cell lung cancer

Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body. It is taken by mouth.

<span class="mw-page-title-main">Sorafenib</span> Chemical compound

Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer, advanced primary liver cancer, FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

<span class="mw-page-title-main">Leflunomide</span> Chemical compound

Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug (DMARD), used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

<span class="mw-page-title-main">Vandetanib</span> Chemical compound

Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase. The drug was developed by AstraZeneca who later sold the rights to Sanofi in 2015.

<span class="mw-page-title-main">Lestaurtinib</span> Chemical compound

Lestaurtinib is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. It is an inhibitor of the kinases fms-like tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), tropomyosin receptor kinase (trk) A (TrkA), TrkB and TrkC.

SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after developing the pioneering kinase inhibitor drug sunitinib (Sutent).

<span class="mw-page-title-main">PARP inhibitor</span> Pharmacological enzyme inhibitors of poly (ADP-ribose) polymerases

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes, thereby interfering with the JAK-STAT signaling pathway in lymphocytes.

<span class="mw-page-title-main">Fedratinib</span> Chemical compound

Fedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis. It is used in the form of fedratinib hydrochloride capsules that are taken by mouth. It is a semi-selective inhibitor of Janus kinase 2 (JAK-2). It was approved by the FDA on 16 August 2019.

<span class="mw-page-title-main">Ceritinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Ceritinib is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014.

<span class="mw-page-title-main">Entrectinib</span> TKI inhibitor used for cancer treatment

Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).

<span class="mw-page-title-main">Tesevatinib</span> Chemical compound

Tesevatinib is an experimental drug proposed for use in kidney cancer and polycystic kidney disease. The drug was first developed by Exelixis, Inc. and was later acquired by Kadmon Corporation. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor, epidermal growth factor receptor 2, vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4).

Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

BeiGene, Ltd. is a China-based drug developer. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

References

  1. ↑ "Company Overview of Kadmon Holdings, LLC". Bloomberg L.P. Retrieved 8 March 2019.
  2. ↑ "Biotechnology Company Overview of Kadmon Corporation, LLC". Bloomberg.com. Archived from the original on January 19, 2013. Retrieved 3 December 2012.
  3. ↑ Bartiromo, Maria. "Sam Waksal, Kadmon Pharmaceuticals CEO". CNBC.com. Retrieved 4 December 2012.
  4. ↑ "Former Imclone Chief Acquires Drug Company". The New York Times. 25 October 2010. Retrieved 7 December 2012.
  5. ↑ "2012 Private financing $50MIL". FORM D. US Securities and Exchange Commission. Retrieved 7 December 2012.
  6. ↑ "Kadmon Corporation Announces the Appointment of Dr. Harlan W. Waksal as President". Kadmon Corporation Announcements. Kadmon Corporation. Archived from the original on 13 November 2014. Retrieved 13 November 2014.
  7. ↑ Lash, Alex (June 13, 2016). "Kadmon Seeks IPO With Unusual Terms That Benefit Waksal, Debt Holders". Xconomy. Retrieved September 25, 2016.
  8. ↑ Carroll, John (June 10, 2016). "Sam Waksal Exited Kadmon With $25M Severance Deal Ahead of IPO". FierceBiotech. Retrieved September 25, 2016.
  9. ↑ "Sam Waksal's Kadmon Holdings shares open below offering price in debut". CNBC LLC. Retrieved 25 September 2016.
  10. ↑ Kadmon Corporation (October 13, 2020). "Kadmon to Transfer U.S. Stock Exchange Listing to Nasdaq" (Press release). Accesswire.
  11. ↑ "France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 bln deal". Reuters.com. 2021-09-08. Retrieved 2021-09-08.
  12. ↑ "35 Studies found for: Kadmon". Clinical Trials.gov. Retrieved March 8, 2019.
  13. 1 2 Pollack, Andrew (31 October 2012). "ImClone Ex-Chief Embarks on New Biotech Venture". The New York Times. Retrieved 8 December 2012.
  14. 1 2 Fitzpatrick Dimond, Ph.D., Patricia (3 November 2010). "Tales from the Biotech Crypt: Sam Waksal Is Back in Business". Insight&Intelligence. Genetic Engineering & Biotechnology News. Retrieved 8 December 2012.
  15. ↑ "Company Overview of Three Rivers Pharmaceuticals, LLC". Bloomberg Businessweek. Bloomberg.com. Archived from the original on January 18, 2013. Retrieved 8 December 2012.
  16. ↑ Ho, Solarina (1 November 2010). "Valeant, Kadmon sign deals on hepatitis C drugs". Thomson Reuters. Archived from the original on March 3, 2016. Retrieved 8 December 2012.
  17. ↑ Chmielecki, Juliann; Pietanza, M. Catherine; Aftab, Dana; Shen, Ronglai; Zhao, Zhiguo; Chen, Xi; Hutchinson, Katherine; Viale, Agnes; et al. (2012). "EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib". Journal of Thoracic Oncology. 7 (2): 434–42. doi:10.1097/JTO.0b013e31823c5aee. PMC   3261336 . PMID   22173702.
  18. ↑ Pietanza, M. Catherine; Gadgeel, Shirish M.; Dowlati, Afshin; Lynch, Thomas J.; Salgia, Ravi; Rowland, Kendrith M.; Wertheim, Michael S.; Price, Katharine A.; et al. (2012). "Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer". Journal of Thoracic Oncology. 7 (5): 856–65. doi: 10.1097/JTO.0b013e31824c943f . PMID   22722787.
  19. ↑ Clinical trial number NCT01559363 for "A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease" at ClinicalTrials.gov
  20. ↑ Riesterer, Oliver; Matsumoto, Fumihiko; Wang, Li; Pickett, Jessica; Molkentine, David; Giri, Uma; Milas, Luka; Raju, Uma (2009). "A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe". Investigational New Drugs. 29 (3): 514–22. doi:10.1007/s10637-009-9361-2. PMID   20024691. S2CID   20865470.
  21. ↑ Liu, Shwu-Huey; Cheng, Yung-Chi (2012). "Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy". Journal of Ethnopharmacology. 140 (3): 614–23. doi: 10.1016/j.jep.2012.01.047 . PMID   22326673.
  22. ↑ "A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 9 August 2014.
  23. ↑ "Company Overview of Nano-Terra". Bloomberg Businessweek. Bloomberg.com. Archived from the original on June 23, 2013. Retrieved 8 December 2012.
  24. ↑ "Kadmon Pharmaceuticals and Nano Terra Announce Worldwide Exclusive Licensing Agreement for Three Novel Product Candidates". Nanowerk.com. Retrieved 8 December 2012.
  25. ↑ Boerma, Marjan; Fu, Qiang; Wang, Junru; Loose, David S; Bartolozzi, Alessandra; Ellis, James L; McGonigle, Sharon; Paradise, Elsa; et al. (2008). "Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin". Blood Coagulation & Fibrinolysis. 19 (7): 709–18. doi:10.1097/MBC.0b013e32830b2891. PMC   2713681 . PMID   18832915.
  26. ↑ Lee, J; Zheng, Y; -von Bornstadt, D; Wei, Y; Balcioglu, A; Daneshmand, A; Yalcin, N; et al. (2014). "Selective ROCK2 Inhibition In Focal Cerebral Ischemia". Annals of Clinical and Translational Neurology. 1 (1): 2–14. doi:10.1002/acn3.19. PMC   3900310 . PMID   24466563.
  27. ↑ Kim, Enoch; Stewart Campbell; Olivier Schueller; et al. (June 2011). "A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein, SLx-4090: Biochemical, Pharmacodynamic, Pharmacokinetic, and Safety Profile". Journal of Pharmacology and Experimental Therapeutics. 337 (3): 775–85. doi:10.1124/jpet.110.177527. PMID   21406547. S2CID   10523856 . Retrieved 8 December 2012.
  28. ↑ Leonardi, R; Alemanni, M (2011). "The management of erectile dysfunction: Innovations and future perspectives". Archivio Italiano di Urologia, Andrologia. 83 (1): 60–2. PMID   21585174.
  29. ↑ Mashiach-Farkash, E; Rak, R; Elad-Sfadia, G; Haklai, R; Carmeli, S; Kloog, Y; Wolfson, HJ (2012). "Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton". Oncotarget. 3 (6): 629–39. doi:10.18632/oncotarget.525. PMC   3442289 . PMID   22776759.
  30. ↑ "Kadmon Acquires First-in-Class Ras Antagonist From Concordia Pharmaceuticals". BioSpace, Inc. Archived from the original on 3 March 2016. Retrieved 8 December 2012.
  31. ↑ "Novel MMP-14 Inhibitor to be Developed in Multi-Indication Oncology Program". Dyax Corporation. Retrieved 8 December 2012.
  32. ↑ Devy, L.; Huang, L.; Naa, L.; Yanamandra, N.; Pieters, H.; Frans, N.; Chang, E.; Tao, Q.; et al. (2009). "Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis". Cancer Research. 69 (4): 1517–26. doi: 10.1158/0008-5472.CAN-08-3255 . PMID   19208838.
  33. ↑ "Capecitabine, prescribing information" (PDF). Retrieved March 8, 2019.
  34. ↑ "Dofetilide capsules, drug label information" . Retrieved March 8, 2019.
  35. ↑ "Entecavir, prescribing information" (PDF). Retrieved March 8, 2019.
  36. ↑ "Ribashpere label information" (PDF). Retrieved March 8, 2019.
  37. ↑ "Temozolomide capsules, prescribing information" (PDF). Retrieved March 8, 2019.
  38. ↑ "Tetrabenazine tablet, prescribing information" (PDF). Retrieved March 8, 2019.
  39. ↑ "Tobramycin prescribing information" (PDF). Retrieved March 8, 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.